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 Abstract 
 
 
 
Study Objective: To study the clinical profile and risk factors in fifty cases 
of drug-induced UGI bleeding. 
Design and Setting: Prospective study, Thanjavur Medical College hospital. 
Patients: Fifty patients admitted with drug-induced hematemesis and/or 
malena. 
Study period: Between March 2006 and August 2007. 
Results: Prevalence of risk factors among the patients suffering from drug-
induced UGI bleeding are as follows:  [1] Old age  > 50 years of age - 66% 
[2] ‘O’ Blood group – 50% [3] Alcoholism – 42% [4] Not using Gastro 
protective agents – 40% [5] Self medication / OTC drugs – 36% [6] Smoking – 
30% [7] Stress and Serious systemic illnesses – 12% [8] Helicobacter pylori – 
12% [9] Known Peptic ulcer disease – 10% [10] High doses / Chronic drug 
intake – 10% [11] Concomitant use of Steroids – 8% and [12] Concomitant 
use of anticoagulants – 4%.  
Conclusion: NSAIDs were the causative drugs for UGI bleeding in all the 
fifty cases studied. All those fifty cases had at least one known risk factor 
and majority (80%) had more than one risk factors of drug-induced UGI 
bleeding.  
Keywords: UGI bleeding, NSAID, hematemesis, malena, PUD and H.pylori 
 
 
  
 CHAPTER - 1  INTRODUCTION 
 
 
 International scenario 
 National scenario 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 It is highly unfortunate that many patients are admitted daily with 
hematemesis and/or malena due to the adverse effects of drugs either 
prescribed or self medicated. Incidence of such cases can be greatly 
reduced if medical practitioners are not only aware of the adverse effects 
of drugs on gastrointestinal tract  but also assess the patients for the risk 
factors of drug-induced UGI bleeding before prescribing these drugs and 
also by properly educating the patients. Non-steroidal anti-inflammatory 
drugs (NSAIDs) including aspirin are among the most frequently prescribed 
drugs worldwide and are available ‘Over-The-Counter’ (OTC) also. Though 
reasonably safe in most cases in prescribed dosages and for short 
durations, these drugs cause serious gastrointestinal toxicity in a large 
number of cases, particularly in older age, history of peptic ulcer disease, 
alcoholism, smoking, stress, poor general health and concurrent use of 
steroids and anticoagulants. They can affect all segments of the 
gastrointestinal tract causing ulcers, severe bleeding, perforation, and 
obstruction. It is therefore imperative for physicians to be aware not only 
about their serious adverse effects but also about the risk factors of drug-
induced gastrointestinal (GI) bleeding and use these drugs with caution and 
only when genuinely indicated.  
1.1 International scenario 
 
World over, 35 million people consume NSAIDs including aspirin on a daily 
basis, and about 30% of these users may develop GI toxicity of sufficient 
degree requiring a physician’s intervention. Conservative calculations 
estimate that approximately 1, 07,000 patients are hospitalised annually 
 for NSAID-related gastrointestinal complications, and at least 16,500 
NSAID- related deaths occur each year among arthritis patients alone. 
Surprisingly, the management of this problem has undergone little change 
in the past 50 years, and is not only frequently under-diagnosed but also 
under-treated (Vikas et al., 2003).  
There were approximately 11.14 crore NSAID prescriptions in the United 
States for the year ending in August 2000 (Retail and Provider Perspective, 
2000). In addition, annual United States sales of over-the-counter oral 
analgesics approach three billion dollars; The prevalence of at least once-
weekly NSAID use among people 65 years old or older has been reported to 
be as high as 70%; half of this group takes at least seven doses a week 
(Talley et al., 1995; Loren, 2001).  
Based on an analysis of acute hospital admissions in one health district in 
United Kingdom, it has been calculated that NSAID-related upper GI events 
account for around 12,000 admissions annually in England and result in 
approximately 2500 potentially avoidable deaths each year. Most of the 
dead were taking higher doses of NSAIDs for long duration or elderly or 
chronic alcoholic or known peptic ulcer disease patients (Belsey, 2003). 
Each year, use of NSAIDs accounts for an estimated 7,600 deaths and 
76,000 hospitalisations in the United States (Fries, 1992) and for 365 deaths 
and 3897 hospitalisations in Canada (Griffin et al., 1991; Statistics Canada 
1992). One percent to three percent of NSAID users have gastrointestinal 
bleeding. It has also been estimated that one third of the cost of treating 
arthritis patients relates to treatment of the side effects of NSAIDs. Older 
age, history of peptic ulcer disease, higher NSAID dose, alcoholism and 
concurrent use of corticosteroids and anticoagulants increase the risk for 
 serious gastrointestinal side effects. Almost all deaths from NSAID related 
gastrointestinal side effects occur in elderly persons; elderly women seem 
particularly susceptible (Robyn et al., 1997).  
 
1.2 National scenario 
 
Indian studies have shown that NSAIDs including aspirin are among the 
most common drugs responsible for adverse drug reactions seen in clinical 
practice. In general, at least 10 to 20 percent of patients have dyspepsia 
while taking an NSAID, although the prevalence may range from 5 to 50 
percent. 
 
 Incidence of new ulcer cases following NSAID intake, ranges from 10% to 
40% for gastric ulcers and 5% - 15% for duodenal ulcers. Most patients are, 
however, asymptomatic (Simon et al., 1999). Seventy percent of the 
patients admitted with drug induced UGI bleeding were > 50 years of age 
(Vikas et al., 2003).  
 
According to prospective data from the Arthritis, Rheumatism, and Aging 
Medical Information System (ARAMIS), 13 of every 1,000 patients with 
rheumatoid arthritis who take NSAIDs for one year have a serious 
gastrointestinal complication (Singh, 1998; Simon et al., 1999). In India, 
quacks also practice these drugs commonly and elderly are the most 
affected (Vikas et al., 2003). 
 
* * * 
 
  
 
 CHAPTER - 2  AIM OF THE STUDY 
 
 
 Aim of the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2.1 Aim of the study  
   
• To study the clinical profile of patients admitted with drug-
induced upper gastrointestinal bleeding. 
 
• To find out the risk factors for the drug-induced UGI bleeding in 
those patients.  
 
• To find out the prevalence of the risk factors among them.  
 
 
* * * 
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 Peptic Ulcer Disease (PUD) results from the imbalance between the 
defensive factors that protect the mucosa and offensive factors that 
disrupt the important gastric mucosal barrier. Many of the primary ulcers 
seen in teenagers are now thought to be associated with Helicobacter 
pylori infection while many of the secondary ulcers are due to use of 
NSAIDs including aspirin. 
 
3.1 Gastric mucosal barrier 
The gastric mucosal barrier is composed of several hierarchically organized 
anatomical and functional components, which mutually contribute to the 
mucosal integrity endangered by the offending luminal acid. The barrier 
consists of three protective components (Source: 
http://en.wikipedia.org/wiki; Last accessed 9 September 2007). The three 
components include: 
(1) A compact epithelial cell lining  
Cells in the epithelium of the stomach are bound by tight junctions that 
repel harsh fluids that may injure the stomach lining. The surface 
epithelial cell layer has properties of easy desquamation, rapid 
regeneration, and production of bicarbonate and phospholipid surfactant. 
The apical cell membrane and the very tight gastric surface mucosal tight 
junctions are generally resistant to acid back-diffusion and may serve 
further to retard hydrogen ion back-diffusion.  
 
 
 (2) A special mucus covering  
Derived from mucus secreted by surface epithelial cells and mucosal neck 
cells this gel-like coating protects the entire surface of the gastric mucosa 
from auto digestion by e.g. pepsin and from erosion by acids and other 
caustic materials that are ingested. The mucus gel contained numerous 
phospholipids, and its luminal surface was coated with a film of 
phospholipid - a surfactant layer which accounts for the remarkably strong 
hydrophobic nature of the gastric luminal surface, which, in turn, provides 
protection against damaging agents. Physico-chemical effect of the very 
high viscosity of the mucus layer and its ability to retain bicarbonate 
secreted by the epithelium with maintenance of a pH gradient is also an 
important factor in protection.  
 
The protective properties of prostaglandins are not based only on their 
antisecretory but also on their cytoprotective action. They stimulate 
glycoprotein and bicarbonate secretion and enhance the microcirculation, 
cellular oxygen supply, restitution and repair (Robert et al., 1979).  
(3) Bicarbonate ions  
The bicarbonate ions are secreted by the surface epithelial cells of the 
stomach and duodenum. The pre-epithelial mucus-HCO3 layer buffers back 
diffusing luminal H+ preventing its entry inside the epithelial cells.   
The peptides epidermal growth factor (EGF) and transforming growth 
factor-alpha (TGF-alpha) have potential role in barrier maintenance by 
binding to a common receptor and stimulate epithelial cell proliferation. In 
the stomach, they also enhance mucus secretion and inhibit acid 
 production. Cytokines such as fibroblast growth factor and hepatocyte 
growth factor are found to enhance healing of gastrointestinal ulcers in 
experimental models (Murphy, 1998).  
Trefoil proteins are a family of small peptides that are secreted 
abundantly by goblet cells in the gastric and intestinal mucosa, and coat 
the apical face of the epithelial cells and render them resistant to 
proteolytic destruction. Trefoil peptides play an important role in mucosal 
integrity, repair of lesions, limitation of epithelial cell proliferation and 
protection of the epithelium from a broad range of toxic chemicals and 
drugs.  
Nitric oxide (NO) plays a crucial role in mucosal integrity and barrier 
function with stimulation of fluid and mucus secretion, enhancement of 
microcirculation and maintenance of epithelial barrier function. It is 
synthesized from arginine through the action of nitric oxide synthease 
(NOS). In several models, co-administration of NO donors such as 
glyceryltrinitrate and NSAIDs results in anti-inflammatory properties 
comparable to NSAIDs alone, but with less damage to the gastrointestinal 
mucosa (Muscara, 1999). Several studies have emphasized the roles of 
NOsynthase (NOS) and COX in maintaining gastric mucosal integrity and 
epithelial restitution (Wallace and Granger, 1992). 
3.2 Drugs causing UGI bleeding 
 
Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) (Table 
3.1) are responsible for most drug-induced GI bleeding. The elderly are 
especially susceptible to NSAID-induced GI bleeding. NSAIDs may cause 
bleeding at any level of the GI tract, but they most commonly do so in the 
 stomach or duodenum. Although the bleeding risk increases in proportion 
to NSAID dose, any amount (including low-dose aspirin taken for 
cardiovascular prophylaxis) may cause bleeding particularly when taken on 
empty stomach. Use of selective serotonin reuptake inhibitors (SSRIs) has 
recently been found to be associated with a higher risk of upper GI 
bleeding, especially in patients who are also taking NSAIDs or low-dose 
aspirin (Dalton et al., 2003). Alendronate and potassium chloride also 
cause upper GI bleeding in very few cases. Role of steroids in ulcerogenesis 
is relatively small, although hemorrhage seems to be the most common 
complication from peptic ulcers in steroid-treated patients (Messer et al., 
1983; Fadul et al., 1988). Anticoagulants do not cause GI bleeding per se, 
but they can unmask or aggravate hemorrhage from preexisting lesions 
(Dalton et al., 2003).  
Table 3.1  Classification of NSAIDs 
Non-steroidal anti-inflammatory drugs  
Salicylates 
Aspirin (Acetylsalicylic Acid), Diflunisal, 
Ethenzamide, Salicin 
Arylalkanoic acids 
Diclofenac, Etodolac, Indometacin, 
Nabumetone, Sulindac 
2-Arylpropionic acids (profens) 
Carprofen, Flurbiprofen, Ibuprofen, 
Ketoprofen, Ketorolac, Loxoprofen, 
Naproxen, Oxaprozin, Suprofen, 
Tiaprofenic acid 
N-Arylanthranilic acids (fenamic acids) Mefenamic acid 
Pyrazolidine derivatives Phenylbutazone 
Oxicams Meloxicam, Piroxicam 
Coxibs 
Celecoxib, Etoricoxib, Parecoxib, 
Rofecoxib, Valdecoxib, Lumiracoxib 
Sulphonanilides Nimesulide 
Topically used products 
Diclofenac, Flurbiprofen, Ibuprofen, 
Indomethacin, Ketoprofen, Naproxen, 
Piroxicam, Suprofen 
 3.3 Mechanisms of drug-induced UGI bleeding 
 
Prostaglandins protect GI mucosa by forming a cytoprotective layer and 
increasing the secretion of bicarbonate ions that neutralise the gastric 
acidity. All therapeutically useful NSAIDs act by inhibiting the synthesis of 
PGs (Tamblyn, 1997). NSAIDs-induced inhibition of prostaglandin 
biosynthesis has resulted in an enhanced production of leukotrienes and 
other products of the 5- lipoxygenase pathway (Whittle et al., 1993). 
These products alter the mucosal barrier with an increased gastric mucosal 
permeability for H+ ions and Na+ ions and reduced transmucosal potential 
difference thereby promoting the formation of erosions and ulcers (Kubes 
et al., 1991; Jimenez et al., 2002). The hydrophobic acid-resistant 
property of the gastric surface active phospholipid layer (SAPL) is rapidly 
attenuated by NSAIDs. Secretion of bicarbonate ions also is inhibited by 
NSAIDs (Knutson and Flemstrom, 1989; Isenberg and Flemstrom, 1991).  
 
Cyclooxygenase has two isoforms, one constitutive (COX-1) and another 
inducible (COX-2). A third isoform (COX-3) has recently been described as 
well. COX-1 is responsible for production of prostaglandins which are 
essential for maintenance of normal endocrine and renal function, gastric 
mucosal integrity and haemostasis. In contrast, COX-2 is virtually 
undetectable in most tissues, but the enzyme activity may be dramatically 
up regulated by inflammatory and mitogenic stimuli (Dequeker et al., 
1998). Conventional NSAIDs cause non-selective inhibition of 
cyclooxygenase, which leads to reduction in bicarbonate secretion and 
reduced mucous production. Coupled with it is vasoconstriction that occurs 
due to NSAIDs, which causes hypoxia and consequent formation of ulcer. 
COX-2 selective inhibitors appear not to be ulcerogenic. Most NSAIDs are 
 weak organic acids and have low pKa. Therefore, they remain unionised in 
stomach and are absorbed appreciably from stomach. However, once they 
breach the cell membranes of stomach cells and reach within, they 
encounter a basic pH (e.g. 7.1). This causes so called ‘trapping’ of the 
drugs inside the cell (Raskin, 1999). This topical effect is considered an 
important mechanism of gastro-duodenal damage associated with their 
use. Even short-term (<1 week) use of aspirin and other nonsteroidal anti-
inflammatory drugs (NSAIDs) can precipitate ulcer-related bleeding. Thus, 
it can be understood to be the disease of the war between the factors 
favoring and those opposing the development of ulcers where the former 
win over the latter.  
 
Aspirin, the only NSAID able to irreversibly inhibit COX-1, also shows 
inhibition of platelet aggregation because it inhibits the action of 
thromboxane-A. Aspirin also causes capillary fragility, increased fibrinolysis 
and a prolonged bleeding time. Role of steroids in ulcerogenesis is small 
and anticoagulants do not cause GI bleeding per se, but both can aggravate 
hemorrhage from preexisting ulcers.  
 
The risk of NSAID induced GI ulcer development is increased in patients 
with advanced age, positive family history, female sex, prolonged use of 
high dose of NSAIDs and concomitant use of anticoagulant drugs and 
gastrotoxic drugs like steroids, Hepatic-renal dysfunction, alcoholism, 
heavy coffee consumption, H pylori infection and poor general health 
(Simon et al., 1999).  
 
 
 
 3.4 Clinical and endoscopic features of drug-induced 
gastrointestinal damage 
 
NSAIDs-induced GI damage is of three main types: 
 
• Superficial damage such as mucosal hemorrhages and erosions. 
• Endoscopically documented non-symptomatic (‘silent’) ulcers. 
• Symptomatic ulcers causing complications such as GI 
hemorrhage.  
 
NSAIDs including aspirin induced ulcers are usually symptom less unless 
complicated. Early symptoms are mild and benign like dyspepsia, nausea, 
vomiting, and anorexia. Pain is usually a late feature. When the ulcer 
starts bleeding hematemesis and/or malena occurs in about 1 to 3 % of 
patients. Most cases of NSAID-induced gastrointestinal ulcers can heal 
spontaneously, even when the drug is continued (Vikas et al., 2003). 
Moreover, it is not usually possible to diagnose these ulcers on the basis of 
clinical features alone, as symptoms suggestive of the ulcers can occur 
frequently in their absence. Elderly patients usually have painless gastric 
ulceration and NSAIDs can mask the symptom of pain (Dhikav, 2001). In 
fact, most elderly patients are referred to physicians for iron deficiency 
anemia due to fecal blood loss.  
 
Few features (Box 3.1), however, can be suggestive of NSAID-induced 
ulceration – like absence of H.pylori infection, anorexia rather than 
abdominal pain, antral location of gastric ulcers, known risk factors and 
prolonged self-medication of the large doses of NSAIDs. Chronic NSAID use 
can increase the risk of ulcer development by 10-30 folds (Andrade et al., 
 1999; Yeoman, 2001). Elderly patients are particularly prone to develop GI 
toxicity and unfortunately they are the most frequent users of this group 
of drugs (Yeoman, 2001).  
 
Box 3.1  Features of NSAID induced GI ulcers  
 
 
 
 
 
 
 
 
 
 
 
 
3.4.1 Oesophagus  
 
Prolonged use of aspirin and most NSAIDs can result in ulceration, 
oesophagitis and even strictures more commonly caused by reflux rather 
than direct action of NSAIDs.  
 
3.4.2 Stomach and duodenum 
 
The features of NSAID ingestion and injury in the stomach and duodenum in 
acute and chronic cases are given in the following Table 3.2 and UGI 
endoscopic view of naproxen induced duodenal ulcer is given as Figure 
3.1. 
 
 
• More than 3 mm in size 
• Deep lesions 
• Prone to complications like bleeding, perforation and obstruction 
• Gastric or duodenal in location 
• Multiple erosions (more than 10) 
• Antral in location 
• Absence of H.pylori 
 Table 3.2  NSAID ingestion and GI injury 
 
Injury type   Gastro-duodenal lesion   Frequency 
 
Acute    mucosal erythema,     
(1-2 weeks)   superficial erosions,  60-100% 
submucosal haemorrhage, 
Increased fecal blood loss 
 
Chronic   gastric antral erosions    
(> 4 weeks)   and ulcers, duodenal  5-30% 
Ulcers and erosions 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 3.1  Naproxen induced duodenal ulcer   
 
 
3.4.3 Small intestine 
 
Ulceration of small intestine other than duodenum has historically been 
difficult to study. One endoscopic study found a prevalence of 26% in 
patients taking these drugs on long-term basis and presenting as cases of 
occult blood loss (Morris et al., 1991). In small intestine, serious lower GI 
events occurred at a rate of 0.9% per year in rheumatoid arthritis patients 
taking non-selective NSAIDs, accounting for 40% of the total adverse GI 
 events in these cases (Loren, 2003). A number of studies suggest that 
ulceration and perforation in small intestine is related to slow release and 
enteric coated formulations of NSAIDs and aspirin (Bjarnason et al., 1987). 
Syndrome of occult blood loss, malabsorption, anemia, and protein losing 
enteropathy has been described in many cases (Gibson et al., 1992).  
 
3.4.4 Large intestine, rectum and anal region 
 
There are only a few cases of NSAID induced damage in this segment of 
GIT. In colon and ano-rectal area they cause colitis, proctitis, and 
presentation similar to inflammatory bowel disease, bleeding (both acute 
and chronic), ulcers, and strictures. Most ulcerative complications like 
perforation are seen in caecum (Carlson et al., 1990). Rectal suppositories 
can result in proctalgia, tenesmus, or watery diarrhoea. Approximately, 10 
- 30% cases can develop these problems (Kurahur et al., 2001).  
 
Arthritis, rheumatism, and ARAMIS study which has prospectively followed 
patient status and outcomes, drug side effects, and the economic impact 
of illness for > 11,000 arthritis patients at eight participating institutions in 
the United States and Canada (Simon et al., 1999) shows that [1] 
osteoarthritis and rheumatoid arthritis patients are 2.5 - 5.5 times more 
likely than the general population to be hospitalised for NSAID related GI 
events; [2] the absolute risk for serious NSAID-related GI toxicity remains 
constant and the cumulative risk increases over time; [3] there are no 
reliable warning signals (> 80% of patients with serious GI complications 
had no prior GI symptoms); [4] independent risk factors for serious GI 
events were age, prednisolone use, NSAID dose, disability level, and 
previous NSAID-induced GI symptoms; and [5] antacids and H2 antagonists 
 do not prevent NSAID-induced gastric ulcers (Doomra and Gupta, 2001; 
Simon et al., 1999). 
 
3.5 Sustained release and enteric coated NSAIDs 
 
Studies have demonstrated increased intestinal permeability with SR and 
EC formulations of all NSAIDs but not with conventional release tablets and 
lower GI bleeding are also more common with them (Choi et al., 1995). 
These formulations claim to cause fewer adverse effects than the 
conventional formulation and that they could be prescribed for patients 
who are most prone to develop such adverse effects. This phenomenon has 
been termed ‘channeling’ and may complicate any interpretation of the 
epidemiology of adverse effects (Leufkens et al., 1992). These lesions are 
often difficult to diagnose on enteroscopy, colonoscopy and barium scans 
as radiological findings can be subtle and easily missed. The prescribing of 
SR NSAID formulations to patients with pre-existing bowel disease (i.e., 
diverticulitis, inflammatory bowel disease) and physiological conditions 
that lead to delayed transit (stenosis, anticholinergic drugs, diverticuli) 
may represent relative or absolute contraindications to such formulations 
and require special clinical considerations (Neal, 1999). Colonoscopic view 
of sustained release diclofenac induced ulcer is shown below in Figure 3.2. 
 
 
 
 
Figure 3.2  Sustained release tablet diclofenac 
induced colonic ulcer 
 3.6 COX-2 selective inhibitors 
 
These newer NSAIDs do not inhibit COX-1 and, therefore, do not have the 
disadvantage of reducing the synthesis of protective prostaglandins. 
Selective COX-2 inhibitors are associated with, at best, a modest decrease 
in the risk of ulcer bleeding. One study showed that the combination of a 
traditional NSAID with a daily proton pump inhibitors (PPI) had the same 
risk of bleeding as that of a COX-2 inhibitor alone (Chan, 2002). One 
potential clinical advantage to using a coxib rather than an NSAID-PPI 
combination involves the prevention of lower GI bleeding (Schnitzer et al., 
2004). In patients taking COX-2 inhibitors, clinical events were less by 54%, 
signifying that these drugs were half as likely to cause adverse events as 
compared to conventional drug (Loren, 2003).  
3.7 Risk factors of drug-induced UGI bleeding 
3.7.1 Old age 
Elderly patients are particularly prone to develop drug-induced GI toxicity 
and unfortunately they are the most frequent users of this group of drugs 
(Yeoman, 2001). The elderly patients are deficient in cytoprotective 
prostaglandins (PGE2 and PGI2) that increase mucous production and 
improve ulcer healing. Moreover, the vascular integrity of the ulcer base is 
poor; therefore, ulcers bleed easily in elderly patients (Dhikav, 2001; 
Dhikav et al., 2002). Osteoarthritis, lumbago, arthralgia, spondyloses, 
rheumatoid diseases and ischemic cardiac diseases are the major 
indications to prescribe NSAIDs and aspirin. Elderly patients usually have 
painless gastric ulceration and NSAIDs can mask the symptom of pain 
(Dhikav, 2001). Almost all deaths from NSAID related gastrointestinal side 
 effects occur in elderly persons and elderly women seem particularly 
susceptible (Robyn et al., 1997). Elderly are at the greatest risk for drug-
induced UGI bleeding and the relative risk at 65 - 74 year age group is 3.8 
times that in the general population (Griffin et al., 1991).  
 
3.7.2   High doses / Chronic drug intake 
 
Chronic NSAID use can increase the risk of ulcer development by 10 - 30 
folds. Chronic aspirin use even in low doses (< 150 mg)  for conditions such 
as cardiovascular prophylaxis causes substantial GI toxicity and patients 
may present with iron deficiency anaemia as chronic use of aspirin can 
cause up to two litres of the blood loss over years (Andrade et al., 1999; 
Yeoman et al., 2001). There is a three-fold increase in the risk for 
dyspepsia in populations consuming high doses of NSAIDs with a four-fold 
increased risk for ulcer (Hawkey, 2000; Ofman et al., 2003). They are also 
responsible for a number of peptic ulcer complications such as bleeding 
and perforation. Severe ulcer complications occur in 5% of chronic NSAID 
users (Halter et al., 2001). The risk of bleeding increases with incremental 
doses of NSAIDs, especially ibuprofen, diclofenac and piroxicam (Singh, 
1999). 
3.7.3 Self medication / OTC drugs 
All NSAIDs including aspirin are now available ‘over the counter’. Patients 
who are unaware of the adverse effects of these drugs, particularly the 
elderly and poorly educated people frequently take these drugs on long 
term. Sometimes, they take these drugs along with prescribed drugs like 
NSAIDs including aspirin, steroids and anticoagulants and occasionally on 
 empty stomach. In India, quacks also practice these drugs commonly and 
elderly are the most affected (Vikas et al., 2003).  
 
Approximately 70 million NSAID prescriptions are written annually in the 
USA and 30 million are dispensed over-the-counter (Graumlich, 2001). A 
large study involving 421 patients admitted to a hospital in UK with upper 
gastrointestinal haemorrhage, who took NSAIDs, revealed that non-
prescription drug use was an important cause of bleed. The most common 
sites of bleeding in that study were gastric ulcers (31%) and duodenal 
ulcers (26%). Therefore, attempts should be made to discourage people 
from taking these drugs on nonprescription basis, especially over a long 
term without clinical supervision (Hawkey et al., 1998; Graham et al., 
2002). Review of post-marketing case reports collected by the FDA’s 
Adverse Event Reporting System (AERS) between 1998 and 2001 identified 
a total of 279 cases of GI bleeding in the United States associated with the 
otc use of NSAIDs: 197 cases for ibuprofen, ketoprofen and naproxen, and 
82 cases for aspirin.  
 
3.7.4  Use of Gastro protective agents 
 
Gastro protective agents (GPAs) are often co-prescribed with NSAIDs, with 
the aim to reduce the associated GI adverse effects. Co-prescribing rates 
range from 17 to 34% in the literature (Rogind, 1997).  
 
Studies have found significant interactions (P < 0.001) between ulcer 
healing drugs and each type of NSAIDs. All the interaction ratios were less 
than 1.0, indicating that the risk of adverse gastrointestinal events 
 associated with taking non-steroidal anti-inflammatory drugs is lower in 
patients also taking ulcer healing drugs than in patients not taking ulcer 
healing drugs (Hooper et al., 2004). 
 
The most commonly used GPAs include proton pump inhibitors (PPI), H2 
receptor antagonists (H2RA), antacids and misoprostol. Although these 
agents have shown to be efficacious to certain extent in prophylaxis and 
treatment of NSAID related GI events, they are not without additional side 
effects and they have cost implications also. Parenteral PPIs are the most 
efficacious of all gastroprotective drugs. Misoprostol has shown to reduce 
the serious upper GI complications by almost 40% (Schnitzer et al., 1995), 
but is poorly tolerated because of its own side effects, mainly diarrhoea 
and abdominal pain. Omeprazole is currently the only PPI licensed for both 
healing and prophylaxis of NSAID-associated ulcers, and usually better 
tolerated than misoprostol (Williams et al., 1989). 
 
3.7.5  Known PUD 
 
Patients with previous H/O complicated or uncomplicated ulcers are 
reported to have the highest absolute risk (around 38.5) for UGI bleeding 
(Lucker et al., 1994). The VIGOR study (Paulsen et al., 1991) involving over 
8,000 patients, has reported the relative risk of having a GI event as 4.0 
for patients with prior UGI events. Patients with past history of peptic 
ulcer disease are having the highest risk to develop NSAID induced ulcer 
bleeding (Loren, 2003). 
 
 
 3.7.6 Alcoholism  
 
Ethanol, a well established ‘barrier breaking agent’, increases mucosal 
permeability by enhancing the conductance of apical Na+ and basolateral 
K+ channels in surface epithelial cells. There is growing evidence that lipid 
peroxidation (LP) could play a significant role in the pathogenesis of 
ethanol-induced gastric mucosal lesions, especially because oxygen 
radicals have been directly implicated in the damage of cell membranes 
after administration of alcohol (Szelenyi and Brune, 1988; Terano et al., 
1989; Kvietys et al., 1990). In a 20 year period the ratio of acute bleedings 
related to ulcers (Gastric ulcer+Duodenal ulcer) decreased from 69% to 
50%, twofold increase in frequency of drug induced acute bleedings (17% 
vs. 35%) and  the ratio of alcohol related bleedings was threefold higher in 
2003 than in the '80s (Gy Pécsi and  Rácz, 2004). As the quantity of alcohol 
consumption increased, the relative risk of upper GI bleeding also 
increased, up to a relative risk of 2.8 in heavy alcohol consumers (Kaufman 
et al., 1999). 
 
3.7.7  Smoking  
 
Smoking increases acid secretion, reduces prostaglandin and bicarbonate 
production, accelerates gastric emptying and decreases mucosal blood 
flow, all favouring ulcerogenesis. It is suggested that, at least in men, 
chronic smoking increases maximal gastric secretion, and therefore could 
have a role in the etiology of duodenal ulcer. Smoking is found to be 
associated with a threefold elevation in the risk of UGI bleeding in patients 
taking NSAIDs compared with no smoking (Peura, 2004). Ulcer healing with 
 H2 receptor antagonists is significantly delayed in smokers compared to non 
smokers. Also the relapse rate of duodenal ulcer is higher in smokers 
compared with non smokers (Korman et al., 1981). 
 
3.7.8  Stress and Serious systemic illnesses  
The foremost effect of stress on the gastrointestinal tract is to decrease 
mucosal blood flow and altered gastric luminal acidity and thereby 
compromises the integrity of the mucosal barrier. Reduced mucosal blood 
flow suppresses production of mucus and limits the ability to remove back 
diffusing protons. As a consequence, significant stress is almost always 
associated with mucosal erosions, particularly in the stomach. A majority 
of these lesions are sub clinical, but gastrointestinal hemorrhage and sepsis 
are not infrequent consequences (Thompson, 1995).  
Stress gastritis and mucosal ulceration are historically associated with (1) 
head injuries with associated elevations in intracranial pressure (Cushing 
ulcer), and (2) burn injuries (Curling ulcer). In critically ill ventilated 
patients, stroke, renal failure, respiratory failure, cardiac dysfunction, and 
coagulopathy disorder were associated with increased risk of significant 
gastrointestinal bleeding whereas enteral nutrition and stress ulcer 
prophylaxis with ranitidine decreased gastrointestinal bleeding (Sprit, 
2003; Martindale, 2005). 
Patients suffering from shock, sepsis, massive burns, severe trauma, or 
head injury can develop acute erosive gastric mucosal changes or frank 
ulceration with bleeding. Classified as stress-induced gastritis or ulcers, 
injury is most commonly observed in the acid-producing (fundus and body) 
portions of the stomach. The most common presentation is gastrointestinal 
 bleeding, which is usually minimal but can be life-threatening. Endoscopic 
studies have demonstrated that such lesions may occur within hours of 
admission to the ICU. About 75 – 100% of ICU patients will have endoscopic 
lesions within 24 hours, but only a small percentage develop stress related 
gastric bleeding (Goldin and Peura, 1996). Overt bleeding, generally 
defined as the occurrence of hematemesis, gross blood or ‘coffee grounds’ 
in the nasogastric aspirate, haematochezia or malena, occurs in 5 – 25% of 
ICU patients (Cook, 1991; Mutlu, 2001). Clinically significant bleeding, 
generally defined as bleeding requiring therapy, overt bleeding 
complicated by hemodynamic instability or a drop in hemoglobin, and 
transfusion of two units of blood within 24 hours, occurs in only 1.5 – 2.6% 
of critically ill patients (Cook et al., 1991). In the ICU patients with UGI 
bleeding, 23.95% had respiratory failure, 19.79% had CNS problems and 
16.79% had cardiovascular dysfunction, 12.27% had Sepsis (Manucherhr, 
2007). The risk of bleeding is about 75% in the first two weeks of ICU 
patients (Deborah et al., 1999). Prolonged mechanical ventilation, renal 
failure and coagulopathy are the most important predictors of stress ulcer 
related bleeding (Deborah et al., 2001).  
 
3.7.9   Concomitant use of other gastro toxic drugs  
 
Glucocorticoids lead to atrophy of all epithelial tissues including gastro 
intestinal mucosa. Their role in ulcerogenesis is relatively small. 
Haemorrhage in steroid takers is related to duration of therapy and dose. 
Although hemorrhage seems to be the most common complication from 
peptic ulcers in steroid-treated patients (Messer et al., 1983; Fadul et al., 
1988), gastroduodenal perforation is also a well-recognized complication 
 attributed to the use of corticosteroids (Koness et al., 1990; Gunshefski et 
al., 1990; Bodner et al., 1990) leading to diffuse peritonitis. 
Association between perforation of colonic diverticula and corticosteroids 
is more underappreciated (Corder, 1987; Arsura, 1990; Chan et al., 1992; 
Weiner et al., 1993). Corticosteroids cause thinning of the intestinal wall, 
diminution of the efficacy of host defenses, and inhibition of protective 
barriers thus increase the potential for the development of diverticulitis 
(Fadul et al., 1988).  
The lack of muscular layer in diverticula and the concomitant alteration in 
structural protein synthesis by corticosteroids would favor diverticular 
perforation (Arsura, 1990). Anticoagulants do not cause GI bleeding per se, 
but they can unmask or aggravate hemorrhage from preexisting lesions 
(Dalton et al., 2003). Steroids and anticoagulants when combined with low 
doses of aspirin or non selective NSAIDs or COX-2 selective inhibitors they 
increase the chances of UGI bleeding many folds (Fabrice et al., 1998).  
3.7.10  ‘O’ Blood group 
 
The observation of a ‘biological gradient’ between the frequency of blood 
group ‘0’ and susceptibility to peptic ulceration may be regarded as 
support for the hypothesis that the blood group substances play a direct 
part in the causation of the disease, or in protecting against it (Balint et 
al., 1957). Patients who do not secrete ABO antigens in their saliva and 
gastric juice are known to be at higher risk of UGI bleeding (Boren et al., 
1993). Boren and colleagues have concluded that blood group antigen 
mediates H.pylori attachment to human gastric mucosa. This study, 
focusing on a North American cohort, suggested that ‘the availability of 
 Helicobacter pylori (H.pylori) receptors might be reduced in individuals of 
blood group A and B phenotypes, as compared to blood group ‘O’ 
individuals’. The large amount of information now available shows that 
stomal, duodenal and gastric ulcers are all commoner in persons belonging 
to blood group ‘O’ than in persons belonging to the other three blood 
groups.  
 
3.7.11 Helicobacter pylori 
Helicobacter pylori, (Figure 3.3) a helical shaped Gram-negative 
bacterium is the only known microorganism that can thrive in the highly 
acidic environment of the stomach. Its helical shape is thought to have 
evolved to penetrate and favor its motility in the mucus gel layer (Samuel, 
1996). H. pylori can be found in the antrum of stomach in 95% of patients 
with a duodenal ulcer and in most patients with a gastric ulcer not 
associated with NSAID use.  
 
 
 
 
 
 
  Figure 3.3 Electron microscopic picture of H.pylori  
H.pylori 
 Survival of H.pylori in the acidic stomach is dependant on urease the 
enzyme which metabolizes urea (which is normally secreted into the 
stomach) to carbon dioxide and ammonia which neutralizes gastric acid. 
The ammonia that is produced is toxic to the epithelial cells, and with 
other products of H.pylori, including protease, catalase, and 
phospholipases, causes damage to those cells (Viala et al., 2004). 
Helicobacter infection is associated with high levels of gastrin and 
pepsinogen and a significant reduction in somatostatin, gastric surface 
hydrophobicity and the phospholipid concentration of the oxyntic mucosa, 
all favoring ulcer formation (Lichtenberger et al., 1997).  
 
One can test non-invasively for H.pylori infection with a blood antibody 
test, stool antigen test, or with the carbon urea breath test (in which the 
patient drinks 14C- or 13C-labelled urea, which the bacterium metabolizes 
producing labelled carbon dioxide that can be detected in the breath). 
However, the most reliable method for detecting H .pylori infection is a 
biopsy check during endoscopy with a rapid urease test, histological 
examination, and microbial culture. Enzyme Linked Immuno Sorbent Assays 
(ELISA) can detect both immunoglobulin G (IgG) and immunoglobulin A 
(IgA) antibodies directed against H. pylori. 
 
The sensitivity of most serologic tests is approximately 95%. Commercial 
ELISA detecting anti H.pylori serum IgG are the serologic tests of choice 
for the primary screening of patients with uncomplicated infections (Laheji 
et al., 1998). Although initially controversial, most evidence now supports 
the assertion that H. pylori and NSAIDs are synergistic with respect to the 
 development of PUD. Eradication of H.pylori in the setting of chronic 
NSAID use is associated with a decreased risk of ulcer bleeding (Lai, 2002).  
A meta-analysis found that H.pylori eradication in NSAID-naive users prior 
to the initiation of NSAIDs was associated with a decrease in peptic ulcers 
(Vergara, 2005). Hence, H.pylori testing and treatment has been 
advocated in naïve aspirin or NSAID users prior to treatment initiation and 
in chronic users with recent ulcer or increased ulcer complication risk 
(Papatheodoridis et al., 2005).  
Although H.pylori eradication has decreased PUD incidence rate in the 
overall population consuming NSAIDs, particularly naïve patients, PPI 
maintenance has been more effective in PUD prevention (Vergara et al., 
2005). Management of H.pylori in patients taking COX-2 selective inhibitors 
can be based upon the same risk assessment as in patients not taking NSAID 
(Chan et al., 2002).  
3.7.12 Genetics and other causes  
More than 20% of patients have a family history of duodenal ulcer, 
compared with only 5 - 10% of control groups. A rare genetic association 
exists between familial hyperpepsinogenemia type-I (a genetic phenotype 
leading to enhanced secretion of pepsin) and duodenal ulcer. The high 
concordance for monozygous twins reared apart, provide data that human 
genetic factors contribute substantially to determining who will be 
infected with H.pylori and who will ultimately be at risk for the spectrum 
of gastritis, peptic ulcer disease, and gastric cancer. Other diseases and 
risk factors associated with PUD are 
 (1) Gastrinoma (Zollinger-Ellison syndrome [ZES])  
  (2)     C 1- esterase deficiency 
 (3)     Neuhauser’s syndrome 
 (4)     Van Allen’s amyloidosis 
 (5) Systemic mastocytosis   
 (6) Basophilia  
 (7) Infections - Herpes simplex virus-1 (HSV-1) and cytomegalovirus 
(CMV) 
(8) Chemotherapy - 5-fluorouracil, methotrexate, and 
     cyclophosphamide 
 (9) Radiation  
 (10) Crack cocaine  
 
3.8 Management of drug-induced UGI bleeding 
3.8.1 Medical management of unstable patient with bleeding 
ulcer  
Stabilisation of the patient with oxygen therapy, infusion of volume 
expanders and blood transfusion are to be done immediately after securing 
the airways. Urgent UGI endoscopy is the treatment of choice in the 
setting of bleeding peptic ulcer for diagnostic and therapeutic reasons. 
Endoscopy provides an opportunity to visualise the ulcer, to determine the 
degree of active bleeding, and to attempt hemostasis by direct measures.  
 Medical management by acid suppression usually serves as an adjunct to 
direct endoscopic therapy. Reducing gastric acidity is believed to improve 
hemostasis primarily through the decreased activity of pepsin, which is 
believed to antagonize the hemostatic process by degrading fibrin clots. 
Many gastroenterologists assert that intravenous PPI therapy maintains 
hemostasis more effectively than intravenous H2RA (Barkun, 2003).  
Parenteral PPI is administered after successful endoscopic therapy for 
ulcers with high-risk signs, such as active bleeding, visible vessels, and 
adherent clots as an 80 mg bolus followed by a continuous 8-mg/hr. 
infusion for 72 hours. This treatment is changed to oral PPI therapy after 
72 hours if no re-bleeding occurs. Parenteral PPI use before endoscopy is 
common practice, and evidence from a recent Canadian database (RUGBE) 
indicates some benefit in decreasing re-bleed rates (Barkun, 2003). 
Concomitant H.pylori infection in the setting of bleeding peptic ulcers 
should be eradicated, as this lowers the rate of re-bleeding (Kikkawa, 
2005).  
3.8.2 Medical management of stable patient with NSAID induced 
ulcer  
Discontinuation of NSAIDs is paramount if it is clinically feasible. In 
general, 6-8 weeks of therapy with a PPI is required for complete healing 
of NSAID ulcers. Misoprostol use significantly reduced the rate of gastric 
ulcers both in short-term and long-term NSAID treatment. Treatment of 
H.pylori infection if present is recommended. For patients who must 
continue with their NSAIDs, PPI maintenance is recommended to prevent 
recurrences even after eradication of H.pylori (Lai, 2002; Lai, 2003). If 
NSAIDs must be continued, changing to a COX-2 selective inhibitor is an 
 option. However, use of a traditional NSAID and once-daily PPI is 
comparable to a selective COX-2 inhibitor with respect to ulcer bleeding in 
patients with a history of PUD (Chan, 2002).  
Concomitant H.pylori infection in the setting of bleeding peptic ulcers 
should be eradicated with lansoprazole 30 mg PO bid or omeprazole 20 mg 
PO bid, plus amoxicillin 1000 mg PO bid and clarithromycin 500 mg PO bid 
for 14 days. Lansoprazole 30 mg PO bid or omeprazole 20 mg PO bid, plus 
metronidazole 500 mg PO bid and clarithromycin 500 mg PO bid for 14 days 
can also be used. New evidence shows that 7-day treatment is adequate in 
those patients who have not failed prior attempts at eradication (Gisbert, 
2005). 
 
3.8.3 Surgical care  
Surgical management of duodenal ulcers is generally reserved for 
refractory ulcers and bleeding ulcers that fail to respond to medical 
management.  
(i)  Endoscopic therapy 
Endoscopic therapeutic intervention is indicated for bleeding duodenal 
ulcers with high-risk signs (e.g., active bleeding, visible vessels, adherent 
clots). Several tools are available to the endoscopist to achieve 
hemostasis; these tools include bipolar cautery, use of a heater probe or 
hemoclips, argon plasma coagulation, and local injection of epinephrine 
and other agents (Lo, 2006). 
 (ii)  Urgent surgical management 
The indications for urgent surgery include the following: (1) failure to 
achieve hemostasis endoscopically, (2) recurrent bleeding despite 
endoscopic attempts at achieving hemostasis (many advocate surgery after 
2 failed endoscopic attempts), and (3) perforation. In general, 5% of 
bleeding ulcers eventually require operative management. Most emergent 
surgical procedures involve simple over-sewing of the ulcer to achieve 
hemostasis. 
(iii)  Elective surgical management 
The indications for elective surgical management (Selective vagotomy, 
highly selective vagotomy) include the following: (1) refractoriness to 
medical treatment, (2) intolerance to medications, and (3) noncompliance 
with medications. With the advent of improved antisecretory therapy and 
with the discovery of H.pylori, elective surgical management of duodenal 
ulcer has become much less common. 
     
* * * 
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 4.1 Materials and methods 
Place of study   : Department of Internal Medicine, 
        Thanjavur Medical College hospital, 
       Thanjavur 
Type of study   : Prospective study 
Period of study   : March 2006 to August 2007 
Ethical Committee approval : The present study was approved by the  
       Ethical Committee 
Collaborating Department : Department of Medical Gastro   
   Enterology 
Consent   : Informed consent was obtained from the  
    participants 
 
 
 
 
 
 
 
 4.2 Selection of patients 
Fifty patients satisfying the following inclusion criteria and not having any 
of the exclusion criteria were taken up for the study. 
4.2.1   Inclusion criteria  
(1) All adult patients of both sexes who were giving definite history of 
intake of drugs and subsequently developed vomiting of frank blood 
or coffee ground coloured vomit and/or passed dark coloured stools 
were chosen for this study.  
(2) Inpatients admitted for other illnesses and who subsequently 
developed UGI bleeding following prescription with drugs like 
aspirin, other NSAIDs, steroids, anticoagulants and other gastro toxic 
drugs were also included.  
(3) Standard definitions of hematemesis and malena were used when 
abstracting data from the clinical records.  
4.2.2   Exclusion criteria  
The following groups of patients were excluded from this study after 
detailed history taking, clinical examination and investigations because of 
the confounding factors which will interfere with the results. 
(1) Patients with past history of hematemesis and/or malena  
(2) UGI endoscopy finding of other causes of UGI bleeding (e.g. Varices, 
Mallory weiss syndrome etc.)  
(3) Bleeding and clotting disorders  
(4) Cirrohosis of liver with portal hypertension  
 (5) Hematological disorders and  
(6) Critically ill patients with life expectancy < 72 hr. 
4.3 Study method 
4.3.1 History 
Patient characteristics like age and sex were noted. Detailed history 
regarding the UGI bleeding like, number of times of hematemesis, 
approximate quantity of blood vomited each time, associated with malena 
or presenting with malena alone and past H/O hematemesis and/or malena 
were obtained. Symptoms of GI toxicity of the drugs, symptoms of common 
diseases that can lead to UGI bleeding and symptoms due to blood loss 
were recorded in the questionnaire. 
 
Detailed history regarding the drug that caused UGI bleeding like  
 
(1)  Generic name of the drug  
(2)  Number of tablets or capsules ingested by the patient  
(3)  Strength of the drug and duration of drug intake  
(4)  Nature of the drug like enteric coated (EC) or sustained release (SR) 
or conventional drug  
(5)  Whether the drug was prescribed by a qualified medical practitioner 
or self medicated / OTC  
(6)  Whether the drug was taken along with a gastroprotective drug like 
antacid, H2 receptor blocker or proton pump inhibitor and  
(7)    Whether the drug was taken on empty stomach, were asked.  
 Detailed history was asked from the patients regarding the risk factors of 
drug-induced UGI bleeding.  
 
(1) Known peptic ulcer disease (diagnosed by a physician or a 
gastroenterologist)  
(2) Alcoholism (those who are consuming alcohol at least 100 ml/day 
regularly for > 3 months)  
(3) Smoking (those patients who are smoking one or more beedies or 
cigarettes per day regularly for > 3 months)  
(4) Stress and serious systemic illnesses of the patients  
(5) Concomitant intake of drugs that may cause or aggravate UGI 
bleeding when taken along with NSAIDs like anticoagulants, steroids, 
biphosphonates and chemotherapeutic agents were obtained  
(6) Past H/O hypertension, diabetes, pulmonary tuberculosis, CAHD, 
asthma, COPD and other serious systemic illnesses were also noted.  
 
4.3.2 Clinical examination 
 
Routine general and systemic examination of the patients was carried out 
with the aim of  
 
(1) Assessing the general condition of the patient 
(2) Confirmation of UGI bleeding by Ryle’s tube aspiration and/or per 
rectal examination 
(3) Assessing severity of blood loss and  
(4) Ruling out other common causes of gastrointestinal bleeding like 
cirrhosis of liver with portal hypertension. 
 
 4.3.3 Laboratory investigations 
 
Routine urine and blood investigations to find out diabetes, renal failure, 
hepatic failure, bleeding and clotting disorders and hematological 
disorders were carried out.  
 
Blood grouping and typing was done not only for transfusion of blood but 
also to find out the role of blood group ‘O’ in drug- induced UGI bleeding. 
Serological test for H.pylori (demonstration of anti- H.pylori IgG) was done 
to find out the association of this bacterium with drug-induced UGI 
bleeding.  
 
4.3.4 Upper gastrointestinal endoscopy 
 
Endoscopy was done for all the patients after overnight fasting, using 
PENTAX video endoscopic system (Figure 4.1), to directly visualise the side 
effects of the drugs on the mucosa of the esophagus, stomach and 
duodenum, like mucosal hemorrhages, erosions, superficial ulcers and 
deep ulcers (Figure 4.2).  
 
The number of ulcers, site and location of ulcers, size of ulcers, bleeding 
or not, healing ulcer or not, clean base of the ulcer or adherent blood clot, 
oozing of blood from the ulcer base and about visible blood vessel were 
studied.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 4.1 PENTAX video endoscopic system at Department of Medical 
Gastro Enterology, Thanjavur Medical College 
 
 
 
 
Ulcer  
 
 
 
 
 
 
Figure 4.2 Endoscopy showing antral ulcer (done on 17-7-2007) 
 
 4.4 Study approach 
 
Number of patients affected, were studied with respect to age group, 
number of bouts of hematemesis, approximate quantity of total blood loss, 
causative drug responsible for UGI bleeding, risk factors of GI bleeding, 
number of individual risk factors in each patients and endoscopic findings 
in the patients. The prevalence of individual risk factors in those fifty 
patients and the prevalence of number of risk factors in those fifty 
patients were studied. 
 
* * * 
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 Study results and observations  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5.1 Study results and observations 
 
 
After studying the fifty cases, results were arrived from the 
proforma of all the patients. Prevalence of drug-induced UGI bleeding 
related to age group and sex were given below in Table 5.1. It was found 
that majority of the patients (48%) were in the age group of 50-64 years. 
 
The number of times of hematemesis the patients had developed and the 
number of patients affected in each group were given below in Table 5.2. 
It was found that percentage of patients with one episode of hematemesis 
and two episodes of hematemesis was 36% each. Patients had maximum of 
five episodes of hematemesis.  
 
Approximate quantities of total blood loss and the number of patients 
affected in each group were shown in Table 5.3. It was observed that 
majority of patients (54%) were having minor UGI bleeding with < 100 ml of 
blood loss and three patients had only malena. 
 
The causative drugs for UGI bleeding and the number of patients who took 
the drugs were shown in Table 5.4. From this table it was found that 
ibuprofen was the causative drug in as high as 19 patients followed by 
diclofenac in 11 patients and aspirin in 8 patients.   
 
Prevalence of endoscopic findings in the patients, with reference to the 
site of lesions was given in Table 5.5. From this table it was observed that 
‘lesions in stomach only’ was the commonest finding (50%). Endoscopy was 
normal in 20% of cases while 20% of cases had lesions in both stomach and 
duodenum. 
 Prevalence of nature of lesions on endoscopic study (Ulcers and erosions) 
was given below in Table 5.6. It was found that ulcers were more common 
(64%) than erosions (16%). 
 
The prevalence of risk factors of drug-induced UGI bleeding among the 
patients was given in Table 5.7. It was observed that old age > 50 years 
was the risk factor with highest prevalence (66%) followed by ‘O’ blood 
group (50%). 
 
Prevalence of patients with drug-induced UGI bleeding with respect to 
number of risk factors was given in Table 5.8. It was observed that all the 
patients (100%) had at least one of the known risk factors and majority of 
patients (32%) had two risk factors of drug induced UGI bleeding. 
 
 
 
Table 5.1 Prevalence of drug-induced UGI bleeding related to age group 
and sex 
 
S.No. Age group Male 
patients 
Female 
patients 
Total % 
1. Age < 19 0 0 0 0% 
2. Age 20 – 34 6 3 9 18% 
3. Age 35 – 49 5 3 8 16% 
4. Age 50  - 64 16 8 24 48% 
5. Age 65 – 79 4 4 8 16% 
6. Age > 80 1 0 1 2% 
7. Number of patients 32 18 50 100% 
 
 
 
 Table 5.2  Frequency of hematemesis  
 
S.No. Number of bouts of Hematemesis Number of patients 
1. One 18 
2. Two 18 
3. Three 4 
4. Four 5 
5. Five 2 
 
 
 
 
Table 5.3  Approximate quantity of blood loss  
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.4  Causative drugs and number of patients  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No. 
 
Quantity of blood loss 
 
Number of patients 
1. < 100 ml 27 
2. 100 to 1000 ml 16 
3. > 1000 ml 4 
4. H/O of Malena alone  3 
S.No. Causative drugs Number of patients 
1. Aspirin  8 
2. Diclofenac 11 
3. Ibuprofen 19 
4. Indomethacin 4 
5. Mefenamic acid 3 
6. Nimesulide 4 
7. Piroxicam 1 
 Table 5.5 Prevalence of site of lesions on endoscopic study  
 
 
 
 
 
 
 
 
 
 
Table 5.6  Prevalence of nature of lesions on endoscopic study 
 
 
 
 
 
 
 
 
 
Table 5.7 Prevalence of risk factors of drug-induced UGI bleeding 
 
S.No Risk factor Male (%) Female (%) Total (%) 
  1. Old age > 50 yrs 21(42%) 12(24%) 33(66%) 
  2. High doses/Chronic drug intake 5 (10%) 0      5(10%) 
  3. Self medication / OTC 11 (22%) 7 (14%) 18(36%) 
  4. Drug intake without GPA 12 (24%) 8 (16%) 20(40%) 
  5. Known PUD 1 (2%) 4 (8%) 5(10%) 
  6. Alcoholism 21 (42%) 0 21(42%) 
  7. Smoking 15 (30%) 0 15(30%) 
  8. Stress & SSI 6 (12%) 0 6(12%) 
  9. Drug intake with Steroids 2 (4%) 2 (4%)      4  (8%) 
10. Drug intake with Anticoagulants 2(4%) 0      2  (4%) 
11. ‘O’ Blood group 16 (32%) 9 (18%) 25(50%) 
12. Positive for H.pylori 3 (6%) 3 (6%) 6(12%) 
S.No Endoscopic findings  Number of patients (%) 
 1. Normal study 10 (20%) 
 2. Lesions in esophagus 0 (0%) 
 3. Lesions in stomach only 25 (50%) 
 4. Lesions in duodenum only 10 (20%) 
 5. 
Lesions in both stomach &  
duodenum 
5 (10%) 
S.No Nature of lesions Number of patients 
1. Erosions 8 (16%) 
2. Ulcers 32(64%) 
3. Normal endoscopy 10 (20%) 
 Table 5.8 Prevalence of patients with drug-induced UGI bleeding with 
respect to number of risk factors 
 
 
 
 
 
Sex distribution among the fifty patients was shown in Figure 5.1. It was 
observed that male patients were more commonly affected than female 
patients. 
 
Age group distribution was shown in Figure 5.2. From the figure It was 
observed that majority of patients were in the age group of 50-64. 
 
Frequency of hematemesis among the patients was shown in Figure 5.3. It 
was found that majority of patients had only one or two episodes of 
hematemesis indicating that NSAIDs-induced ulcers heal rapidly once the 
offending drug was stopped.  
 
S.No. 
Number of  
risk factors 
Male Patients 
        (%) 
Female Patients
         (%) 
 Total (%) 
1. 0 0 0 0 (0%) 
2. 1 1 (2%) 9 (18%) 10 (20%) 
3. 2 11 (22%) 5 (10%) 16 (32%) 
4. 3 7 (14%) 2 (4%) 9 (18%) 
5. 4 9 (18%) 2 (4%) 11 (22%) 
6. 5 2 (4%) 0 (0%) 2 (4%) 
7. 6 0 (0%) 1 (2%) 1 (2%) 
8. 7 1 (2%) 0 (0%) 1 (2%) 
 Prevalence of causative drugs was given in Figure 5.4 and it was found 
that the most commonly prescribed drugs ibuprofen, diclofenac and aspirin 
were responsible for majority of the cases.  
 
Number of prescribed patients who developed UGI bleeding and the 
number of self medicated developing UGI bleeding was shown in Figure 
5.5 and it was observed that self medication was also an important risk 
factor of drug- induced UGI bleeding. 
 
Prevalence of site of lesions on endoscopic study was given in Figure 5.6.  
It was observed from the figure that ten patients were having normal 
endoscopic study, twenty five patients were having lesions in stomach 
only, ten patients were having lesions in duodenum only and five were 
having lesions in both stomach and duodenum. None of the patients 
studied, had lesions in the esophagus. The ten patients who had normal 
endoscopic study were done UGI endoscopy three to five days later. 
 
Prevalence of nature of lesions on endoscopic study was given in Figure 
5.7. It was found that ulcers were more common than erosions. 
 
Prevalence of each individual risk factor in patients with drug-induced UGI 
bleeding was shown in Figure 5.8. It was observed that old age > 50 years, 
‘O’ blood group, not taking gastroprotective agents along with NSAIDs, self 
medication and getting NSAIDs over the counter, taking NSAIDs despite 
knowing the peptic ulcer problem and H.pylori infection were the major 
risk factors present in female patients while the male patients also had 
other major risk factors like alcoholism, smoking and chronic drug intake.  
 Prevalence of patients with drug-induced UGI bleeding with respect to 
number of risk factors was shown in Figure 5.9. It was found that higher 
the number of risk factors the lower the number of female patients and 
that majority of male patients were having two to four risk factors while 
the majority of female patients were having one or two risk factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.1 Sex distribution 
 
 
 
 
 
Figure 5.2 Age group distribution 
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 Figure 5.3 Frequency of hematemesis  
 
 
Figure 5.4 Prevalence of causative drugs  
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 Figure 5.5 Prescription vs. Self medication / OTC 
 
 
Figure 5.6 Prevalence of site of lesions on endoscopic study  
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Figure 5.7 Prevalence of nature of lesions on endoscopic study 
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Figure 5.8 Prevalence of individual risk factors among the patients 
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Figure 5.9 Prevalence of patients with drug-induced UGI bleeding with 
respect to number of risk factors 
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 CHAPTER - 6  DISCUSSION 
 
 
 Discussion  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.1 Discussion 
 
6.1.1   Sex 
 
Out of the fifty patients studied, thirty two were male patients which gave 
the male: female ratio of 1.77:1. In a Scandinavian study, it was found that 
the incidence of drug induced UGI bleeding was twice as high among men 
as among women (Oliver et al., 1997). In a Sri Lankan study it was 
discussed that the incidence of drug induced UGI bleeding among male and 
female patients was in the ratio of 1: 2.125 (Satarasinghe and Jayamaha, 
2000).   
 
6.1.2  Age 
 
The percentage of number of patients in the age group of equal to or 
above 50 yrs of age was 66%, comprising 2/3 of all the patients. In this 
present study, it was found that the elderly patients > 50 years of age 
were frequently prescribed NSAIDs and aspirin for their orthopedic and 
cardiac problems and the relative risk was 2.0 times higher than the 
others.  
 
In the early study by Griffin et al., (1991) the relative risk for elderly 
patients  with age group of > 65 years was 3.8 times than the others.  
 
A Sri Lankan study found that majority of the patients were in the middle 
age or elderly group, prone to high risk of NSAID induced gastric injury 
(Satarasinghe and Jayamaha, 2000).  
 
 In an Indian study by Vikas et al., in 2003, seventy percent of the patients 
admitted with drug induced UGI bleeding were > 50 years of age. The 
lesser average life span of Indian population, early onset of arthralgia, 
arthritis, low backache, sciatica, spondyloses and coronary artery heart 
diseases in our population may be the reasons for the higher prevalence of 
drug induced UGI bleeding at an earlier age compared to the western 
population (Vikas et al., 2003).  
 
   
6.1.3 Severity of hematemesis 
 
 
Percentage of patients with one or two episodes of hematemesis was 72% 
and 54% of the patients admitted with drug-induced UGI bleeding were 
having minor UGI bleeding (< 100 ml). Only 8% of the patients had severe 
UGI bleeding (> 1000 ml) in the present study and majority of those 
patients were found to have four or more risk factors. None of the patients 
studied, died during the hospital stay.  
 
NSAID-induced peptic ulcers usually heal very rapidly once the offending 
drug is stopped. Mortality is high in patients, already known to have peptic 
ulcer disease, who are taking NSAIDs in high doses for prolonged period and 
in patients who are concomitantly taking steroids and anticoagulants 
(Loren, 2001). 
 
 
 
 
 
 6.1.4 Causative drugs 
 
Ibuprofen was responsible for the majority of cases of drug-induced UGI 
bleeding in the fifty patients studied accounting for 38% and the doses fell 
within safe limits.  Diclofenac was the second fashionable drug (22%), and 
both drugs had already been proved to be safer than the other 
nonselective NSAIDs in the previous studies.  Aspirin was hardly ever used 
in the management of chronic arthritic conditions and was mainly 
prescribed for cardiac patients in low doses (150 mgs). Ibuprofen and 
diclofenac are preferred by many practitioners because of their less GI 
toxicity compared to other nonselective NSAIDs. These three drugs were 
responsible for 76% of all the cases of drug-induced UGI bleeding and tell 
us the fact that all NSAIDs including aspirin even in safer doses can cause 
serious GI complications. In the present study all the patients were 
prescribed or self medicated within the safer limit of doses. Aspirin was 
the only drug found to have been taken regularly for prolonged period, in 
this study. 
 
Although the bleeding risk increases in proportion to NSAID dose, any doses 
of NSAIDs (including low-dose aspirin taken for cardiovascular prophylaxis) 
may cause bleeding (Dalton et al., 2003). 
 
It was found in the study that the NSAID nimesulide which was banned few 
years back was still prescribed in 6% of cases and it was available over the 
counter in 2% of cases and nimesulide was responsible for UGI bleeding in 
8% of the patients studied. Among the eighteen patients who got the drugs 
over the counter, many chose ibuprofen (9 patients) or diclofenac (8 
patients). None of the patients in this study took COX-2 selective inhibitor. 
 6.1.5   High doses / Chronic drug intake  
 
In the present study, only 10% of the patients were taking drugs for longer 
period > 3 months. All of them were prescribed patients taking aspirin for 
their cardiac illnesses. Other NSAIDs were not taken by the patients 
regularly for prolonged period. All the patients studied, were prescribed or 
self medicated within the safer limit of doses.  
 
The risk of bleeding increases with incremental doses of aspirin and most 
NSAIDs especially with ibuprofen, diclofenac and piroxicam (Singh, 1999). 
Risk of deaths due to NSAIDs induced severe GI bleeding, is high in patients 
taking higher doses of NSAIDs for years (Laine 1999). 
 
 
6.1.6   Self medication / OTC  
 
A large study involving 421 patients admitted to a hospital in United 
Kingdom with upper gastrointestinal haemorrhage, who took NSAIDs, 
revealed that non-prescription drug use was an important cause of bleed in 
30% of patients (Hawkey et al., 1998; Graham et al., 2002).  
 
In the present study, self medication was observed in 36% of patients. 
Seven of the eighteen female patients studied (38.89%), took NSAIDs on 
their own, while eleven of the thirty two male patients (34.38%) were 
found self medicated. Ibuprofen (50%) and diclofenac (44.44) were the 
drugs preferred by seventeen of the eighteen patients who took the drug 
over the counter. 
 
 6.1.7    Drug intake without Gastroprotective agents 
 
Gastroprotective agents are often co-prescribed with NSAIDs, with the aim 
to reduce the associated GI adverse effects. Co-prescribing rates range 
from 17 to 34% in the literature (Rogind et al., 1997). The most commonly 
used GPAs include proton pump inhibitors (PPIs), H2 receptor antagonists 
(H2RA) and misoprostol. Parenteral PPIs are the most efficacious of all the 
gastroprotective drugs in patients with NSAIDs-induced UGI bleeding (Loren 
2001).  
 
In the current study, 40% of the patients didn’t take a gastroprotective 
drug along with NSAID. Others took either antacids (34%) or H2 receptor 
antagonists (26%). 
 
6.1.8   Known PUD 
 
The use of any NSAID, including low-dose (i.e., ≤ 150 mg/day) aspirin, was 
associated with an increased risk (18 folds higher risk when compared to 
normal population) of GI bleeding in a patient with known peptic ulcer 
disease and NSAIDs including aspirin should never be taken on an empty 
stomach (Lanas et al., 2000).  
 
In the present study, one male patient and four female patients despite 
knowing about previous episode of peptic ulcer disease, took NSAID and 
developed UGI bleeding. Three of those female patients took the NSAIDs 
without prescription. Twenty percent of the total number of patients 
studied gave history of NSAID intake on empty stomach. These findings 
suggest that physicians must always enquire patients about the past history 
 of PUD before prescribing any NSAID and that they should educate the 
patients about the adverse effects of the drugs they are prescribing.   
 
6.1.9 Alcoholism 
 
Ethanol is known to cause gastric mucosal irritation and nonspecific 
gastritis. Nonsteroidal anti-inflammatory drugs (NSAIDs) and alcohol 
consumption increase the risk for major upper gastrointestinal bleeding. 
Kaufman and associates studied the relationship between aspirin and 
ibuprofen in upper GI bleeding with various levels of alcohol consumption. 
As the quantity of alcohol consumption increased, the relative risk of 
upper GI bleeding also increased, up to a relative risk of 2.8 in heavy 
alcohol consumers (Kaufman et al., 1999).  
The use of aspirin increased the risk at all levels of alcohol consumption. 
With regular use, the relative risk for upper GI bleeding in alcohol 
consumers taking more than 325 mg of aspirin per day was 7.0. Regular use 
of ibuprofen was also found to increase the relative risk for upper GI 
bleeding in alcohol consumers (Kaufman, et al., 1996).  
In the present study alcoholism was found in 42% of patients with UGI 
bleeding all of them were males. Also, alcoholism emerged as the third 
most important independent risk factor for UGI bleeding in this study.  
 
 
 
 6.1.10  Smoking  
 
Smoking is found to be associated with a threefold elevation in the risk of 
UGI bleeding in patients taking NSAIDs compared with no smoking (Peura, 
2004). Ulcer healing with H2 receptor antagonists is significantly delayed in 
smokers compared to non smokers. Also the relapse rate of duodenal ulcer 
is higher in smokers compared with non smokers (Korman et al., 1981). 
One study reported that after ulcers healed, about half of nonsmokers 
experienced a relapse of their ulcer disease after one year, but that all 
heavy smokers relapsed after three months. However, smoking in the 
setting of H.pylori infection may increase the risk of relapse of PUD 
(Sonnenberg, 1981). 
 
In the current study, 30% of the patients were having the risk factor of 
smoking and all of them were males. Only one smoker in this study had 
H.pylori infection and known peptic ulcer disease. 
  
6.1.11 Stress and Serious systemic illnesses 
 
About 75 – 100% of ICU patients will have endoscopic lesions within 24 
hours, but only a small percentage develop stress related gastric bleeding 
(Goldin and Peura, 1996). In the ICU patients with UGI bleeding, 23.95% 
had respiratory failure, 19.79% had CNS problems and 16.79% had 
cardiovascular dysfunction, 12.27% had Sepsis (Manucherhr, 2007). 
 
 
 In the present study 12% of patients were having serious systemic illnesses. 
They had been suffering from coronary artery heart diseases (4 patients) or 
COPD with respiratory failure (2 patients) and all of them were male 
patients. 
 
6.1.12 Concomitant use of Steroids 
 
Glucocorticoids lead to atrophy of all epithelial tissues including gastro 
intestinal mucosa and their role in ulcerogenesis is relatively small. 
Haemorrhage in steroid users is related to duration of therapy and dose 
(Messer et al., 1983; Fadul et al., 1988). Steroids when combined with low 
doses of aspirin or non selective NSAIDs or COX-2 selective inhibitors 
increase the chances of UGI bleeding four folds (Fabrice et al., 1998).  
In the present study, concomitant intake of steroids contributed as a risk 
factor in eight percent of cases of NSAIDs induced bleeding. The patients 
who took steroids along with NSAIDs were taking steroids for more than 
three months in optimal doses for their respiratory problems.  
6.1.13 Concomitant use of Anticoagulants 
Aspirin, in low doses (150 mg) was prescribed along with injection Heparin 
in 4% of patients studied, for CAHD for four days and was able to cause 
moderate UGI bleeding (100 ml to 1000 ml) in them. This is one of the 
frequently used combinations in CAHD patients (in ICCU and general ward 
inpatients) and this study makes us alert about the increased risk of aspirin 
induced UGI bleeding when taken along with anticoagulant.  
 
 Anticoagulants do not cause GI bleeding per se, but they can unmask or 
aggravate hemorrhage from preexisting lesions (Dalton et al., 2003). 
6.1.14 ‘O’ Blood group 
Patients who do not secrete ABO antigens in their saliva and gastric juice 
are known to be at higher risk of UGI bleeding. In an earlier study 52.8% of 
patients with bleeding duodenal ulcers were found to have ‘O’ blood group 
(Boren et al., 1993). Study by Kuyvenhoven et al., in 1999 didn’t find any 
potentiation of ‘O’ blood group on NSAIDs induced ulceration. 
In the present study half of all those fifty patients studied were found to 
have ‘O’ blood group. It had emerged as the second most important 
independent risk factor.  
6.1.15 H.pylori 
 
So far, both positive (Aalykke et al., 1999) and negative (Santolaria et al., 
1999; Stack et al., 2002; Okan et al., 2003) interactions have been 
reported between H.pylori infection and the use of NSAIDs, while other 
reports have suggested that H.pylori and NSAIDs are independent risk 
factors in the etiology of UGI bleeding (Cullen et al., 1997; Pilotto et al., 
1997; Labenz et al., 1999; Wu et al., 1999; Hunang et al., 2002).  
 
Most evidence now supports the assertion that H.pylori and NSAIDs are 
synergistic with respect to the development of PUD. Eradication of 
H.pylori in the setting of chronic NSAID use is associated with a decreased 
risk of ulcer bleeding (Lai, 2002).  
 
 In the current study, the percentage of patients with drug-induced UGI 
bleeding, affected with H.pylori was only 12%. 
 
6.1.16 Relationship between OTC and GPA 
 
Number of patients who were self medicated was eighteen, while the 
number of patients who didn’t take a gastroprotective agent was twenty. 
Among the eighteen self medicated patients there were two male patients 
and one female patient who took gastroprotective drugs along with NSAID. 
It was found that majority (15) of those taking drugs on their own (18) 
didn’t take a gastroprotective agent.  
 
There appears to be a direct relationship between self medication and not 
taking a gastroprotective drug along with NSAIDs (Lai, 2002). 
 
6.1.17 Endoscopic findings 
 
In the present study, endoscopy was normal in 20% of cases. They had 
undergone delayed UGI endoscopy by three to five days and they had only 
minor UGI bleeding. On follow up they didn’t develop further bleed. 
 
NSAID-induced peptic ulcers usually heal very rapidly once the offending 
drug is stopped (Loren, 2001). 
 
No one had findings in esophagus. Gastric lesions alone were found in 50% 
of cases, duodenal lesions alone were found in 20% of cases and in 10% of 
cases, findings were seen in both stomach and duodenum. Erosions in 
stomach were seen in 10% of patients while ulcers in stomach were seen in 
 40% of patients. Similarly, erosions in duodenum were seen in 4% of 
patients while duodenal ulcers were found in 16% of cases. Among the 
patients with lesions in both stomach and duodenum, erosions were seen in 
2% of patients and ulcers were found in 8% of cases. Hence, ulcers were 
found to be more common (64%) than erosions (16%).  
 
In an Indian study, incidence of new ulcer cases following NSAID intake, 
ranges from 10% to 40% for gastric ulcers and 5% - 15% for duodenal ulcers 
(Simon et al., 1999). 
 
Studies have demonstrated increased intestinal permeability with SR and 
EC formulations of all NSAIDs but not with conventional release tablets and 
lower GIT bleeding are also more common with them (Choi et al., 1995). 
 
In the present study only one female patient was prescribed ‘sustained 
release’ tablet diclofenac 100 mg, and on endoscopy she was found to 
have lesions in both stomach and duodenum.  
 
6.1.18 Prevalence of number of risk factors 
 
Of the twelve total numbers of risk factors studied, patients had number of 
risk factors ranging from one to seven and no one was without a risk 
factor. Eighty percent of the patients had two or more risk factors of drug- 
induced UGI bleeding. Majority (28 out of 32) of the male patients had two 
to four risk factors and majority (14 out of 18) of the female patients had 
one or two risk factors only. 
 
* * *  
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  Conclusion  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7.1 Conclusion 
The present study on drug-induced UGI bleeding concludes that 
 
(1)  Non-steroidal anti-inflammatory drugs were the causative drugs for 
UGI bleeding in all the fifty cases studied.   
 
(2) Among the NSAIDs, the prevalence of causative drugs was as follows: 
Ibuprofen was the causative drug in 38% of cases, diclofenac in 28%, 
aspirin in 16% and other non selective NSAIDs in 18% of cases.  
 
(3) In endoscopic study, ‘gastric lesions only’ was found in 50% (highest 
percentage); next to that ‘duodenal lesions only’ in 20% and both 
gastric and duodenal lesions in 10%. Endoscopy was normal in 20%.  
 
(4) Regarding the nature of lesions, ulcers were more common (64%) 
than erosions (16%). 
 
(5) All the fifty cases had at least one known risk factor and majority 
(80%) had more than one risk factors of drug induced UGI bleeding. 
 
(6) The prevalence of risk factors was as follows [1] Old age  > 50 years 
of age - 66% [2] ‘O’ Blood group – 50% [3] Alcoholism – 42% [4] Not 
using Gastroprotective agents – 40% [5] Self medication / OTC drugs 
– 36% [6] Smoking – 30% [7] Stress and Serious systemic illnesses – 
12% [8] Helicobacter pylori – 12%  [9] Known Peptic ulcer disease – 
10% [10] High doses / Chronic drug intake – 10% [11] Concomitant 
use of Steroids – 8% [12] Concomitant use of Anticoagulants – 4%. 
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 Appendix A: Proforma – Study on Drug-induced UGI Bleeding 
Department of Internal Medicine, Thanjavur Medical College 
 
1. Name:    2. Age:   yrs 3. Sex:  M          F  
4. IP No:                                               5. Ward:                       6. Unit: 
   
7. Occupation:                                      8. Monthly income:                           
 
9.  Height (in cm)  10. Weight (in Kg)    11. BMI   
 
12. Hematemesis and malena 
S.No. History Details 
(a). No. of times blood vomited  
(b). Date and time of Hematemesis  
(c). Quantity of blood loss each time  
(in milli litre) 
(1) (2)                  (3) 
(4)             (5)           (6) 
(d). Total quantity of blood loss  (1)< 100ml  (2)100 to 1000ml  (3)>1000ml  
(e). H /o Malena  
(f). Past H/o Hematemesis / Malena  
 
13. Other symptoms  
 
(a) Abdominal pain  (b) Heart burn    
(c) Dysphagia   (d) Abdominal lump  
(e) Waterbrash /vomiting (f) Dyspepsia  
(g) Jaundice   (h) Any other bleeding tendency  
(i)  Syncope    (j) Palpitation  
 
14. Drug history  
S.No. Drug history (a) Aspirin (b) COX-1 
Inhibitor 
(c) COX-2 
Inhibitor 
(d) Others 
(specify) 
1. Strength of tablet     
2. No. of tablets taken     
3. Duration of intake     
4. Prescribed or not?     
5. Taken on empty stomach?     
6. EC/SR?     
7. Concomitant use of  
Gastro protective drug?  
    
 
15. Triggers  
 
(a) Known PUD  (b) Alcoholism  (c) Smoking     (d) Stress & SSI 
 
(e) Steroids   (f) Anti coagulants    
      
 
16. Past history 
 
(a) HT  (b) DM  (c) PT  (d) CAHD  (e) H/O Asthma/COPD  
 
(f) Others (Specify) 
   
  
     
 
 
 17. Clinical examination  
 
(a) Oriented          (b) Dyspnea          (c) Pallor         (d) Icterus         (e) Pedal edema 
 
(f) Purpura/Petechiae         (g) Pale, Sweaty extremities         (h) Signs of liver failure  
 
(i) Sternal tenderness (j) RT aspiration showing GI bleed          (k) PR for malena  
 
18. Vital signs  
 
(a) Pulse:      /min  (b) BP (supine):          mmHg      (c) BP (standing):            mmHg 
 
(d) Respiratory rate:       /min               (e) Temp:      ℃ 
 
19. Examination of systems: 
 
(a) Abdomen   : 
 
 
(b) Respiratory system  : 
 
(c) Cardiovascular system : 
 
(d) Central Nervous System : 
 
20. Investigations: 
 
(i) Urine: (a) Albumin     (b) Sugar    (c) Bile salt      (d) Bile pigment  
 
(ii) CBC   (a) Hb:                  (b) TC:                 (c) DC: P        L        M         E        B         
 
              (d) RBC:               (e) Platelet 
 
(iii) Blood(a) Group:              (b) Bleeding time:            (c) Clotting time: 
   (d) Bl.urea:             (e) Bl.sugar(R):            (f) Sr.Creatinine:    
   (g) Sr.Na+:         (h) Sr.K+ 
(iv) LFT: (a) SGOT                 (b) SGPT           (c) Sr.Bilirubin            (d) Alk. Phosphatase 
              (e) Sr. Protein         (f) Sr. Albumin 
(v) Chest X-Ray: 
(vi) ECG: 
 
21. Test for H.Pylori (anti H.pylori IgG): 
 
22. Upper GI Endoscopy: MGE No.:  Date: 
 
(a) Oesophagus:     
      
(b) Stomach: 
 
(c) Duodenum: 
  
   
  
    
 
 Appendix B: Master Chart 
 
 
Note: (M) - Male; (F) - Female; (Y) –Yes; (N) – No; (Nl) - Normal; (+) - Findings present; (-) - Negative; (D) – Days; (W) – Weeks; (Mo) – Months; 
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1. Pitchaikannu 84 M 953160 21.4 3 2 Y N Aspirin 150 180 6Mo N N N N N N Y Y Y Y Y N N Y Y 7 
2. Ramalingam 62 M 953397 23.6 1 1 N N Ibuprofen 400 6 2D Y N N N N Y Y N N N N Y N N N 3 
3. Govindharaj 50 M 946554 24.4 2 2 Y N Diclofenac 100 10 5D Y N N Y N Y N N N N N N N N N 4 
4. Shajahan 63 M 945403 31.1 1 1 Y N Aspirin 150 90 3Mo N N N N N Y Y N N N Y Y N Y N 4 
5. Sudhakar 25 M 951573 22.4 3 2 Y N Nimesulide 100 3 1D N N N Y N Y N N N N N N N N N 2 
6. Gowri 45 F 951537 23.2 2 3 Y N Diclofenac 100 4 2D Y Y Y Y Y N N N N N N N N N N 3 
7. Venkatachalam 50 M 944412 23.3 1 2 N N Heparin/Aspirin 150 4 4D N Y N N N N Y Y Y Y N Y N Y Y 5 
8. Suresh 25 M 945253 22.8 1 1 N N Diclofenac 50 2 1D N Y N Y N Y N N N N N N N N N 3 
9. Vellaiammal 50 F 946071 26.6 1 1 Y N Diclofenac 50 14 1W Y N N Y Y N N N Y N N N N N Y 4 
10. Rajathi 28 F 889497 25.6 1 1 N N Ibuprofen 400 10 4D N Y N N N N N N N N N N N N N 1 
11. Antony samy 70 M 889576 19.6 2 2 Y N Nimesulide 100 6 3D N Y N N N N Y N N N N Y N N N 3 
12. Ganesan 63 M 889719 25.3 1 1 N N Ibuprofen 400 8 3D N N N N N Y Y N N N N N N N N 2 
13. Ramu 60 M 891427 24.1 2 2 Y N Indomethacin 250 4 2D N N N N N Y N N N N N N N N N 2 
14. Radha 50 F 900775 23.9 1 1 Y N Ibuprofen 400 6 2D Y N N Y N N N N N N N N N N N 3 
15. Shankar 67 M 901035 24.2 2 2 Y N Aspirin 150 90 3Mo N Y N N N Y N N N N N Y N Y N 3 
16. Abirami 27 F 902656 20.3 1 1 N N Ibuprofen 400 5 2D N N N Y N N N N N N N N N N N 2 
17. Adhirai 68 F 904008 24.4 1 1 Y N Mefenamic acid 250 8 3D N N N N N N N N N N N N N N N 2 
18. Panneerselvam 60 M 905804 25.4 2 1 Y N Aspirin 150 150 5Mo N N N N N N Y Y N N N Y N Y N 3 
19. Arulmary 37 F 905351 21.4 1 1 N N Ibuprofen 400 4 2D Y N N Y N N N N N N N N N N N 2 
20. Tamilselvan 35 M 902920 28.2 1 1 N N Diclofenac 50 5 3D Y N N Y N Y N N N N N N N N N 4 
21. Sarasu 59 F 903313 23.1 2 1 Y N Ibuprofen 200 15 6D Y N N N N N N N N N N N N N N 1 
22. Amutha 34 F 932387 25.3 2 1 Y N Ibuprofen 400 7 3D N N N N N N N N N N N N N N N 1 
23. Sarasu 64 F 932287 23.7 1 1 N N Piroxicam 20 4 4D N N N N Y N N N N N N N N N N 2 
24. Selvendhran 28 M 932531 24.4 1 1 N N Diclofenac 50 5 3D Y Y N Y N N Y N N N N N N N N 3 
25. Chandra 70 F 935141 22.3 2 2 Y N Ibuprofen 400 12 6D Y N N Y N N N N N N N N N N N 4 
 Appendix B: Master Chart (Continued…) 
 
18. vital signs       20. Investigations 
 
22. UGI Endoscopy 
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1. Pitchaikannu 953160 90 130/90 18 - - 9.6 7600 1.8 O+ 3’05 5’20 36 107 1.4 Nl Nl + - 1412/07 27/8/07 Nl + Nl 
2. Ramalingam 953397 78 130/86 15 - + 9.2 7300 1.4 AB+ 2’50 6’10 42 278 1.3 Nl Nl Nl - 1441/07 30/8/07 Nl + Nl 
3. Govindharaj 946554 108 90/60 16 - - 9.8 6500 1.1 O- 2’45 5’15 29 94 1.1 Nl Nl Nl - 1257/07 28/6/07 Nl + + 
4. Shajahan 945403 112 120/84 17 - - 10.2 10500 1.4 O+ 3’00 6’30 35 125 1.1 Nl + + - 1232/07 21/6/07 Nl Nl + 
5. Sudhakar 951573 88 124/84 15 - - 8.2 4800 2.1 A+ 2’50 6’20 37 108 0.9 Nl Nl Nl - 1403/07 7/8/07 Nl + Nl 
6. Gowri 951537 90 11O/70 15 - - 6.6 3600 1.5 A+ 3.15 7’10 40 92 1.2 Nl Nl Nl - 1396/07 2/8/07 Nl + + 
7. Venkatachalam 944412 106 134/70 16 - - 7.6 6200 1.5 O- 3’50 6’00 38 106 1.0 Nl + + - 1098/07 14/6/07 Nl + + 
8. Suresh 945253 100 96/66 16 - - 8.7 7100 1.9 O+ 2’45 5’15 35 98 1.6 Nl Nl Nl - 1221/07 21/6/07 Nl + Nl 
9. Vellaiammal 946071 106 106/70 15 - - 8.2 6200 1.7 AB+ 2’40 5’30 33 72 0.9 Nl + + - 1208/07 26/6/07 Nl + Nl 
10. Rajathi 889497 110 96/60 16 - - 9.1 4900 1.6 AB- 4’10 5’40 29 115 0.9 Nl Nl Nl + 1214/06 8/6/06 Nl Nl Nl 
11. Antony samy 889576 86 130/84 17 - - 7.3 4300 1.4 O- 3’30 5’00 45 153 1.1 Nl Nl Nl - 1229/06 8/6/06 Nl + Nl 
12. Ganesan 889719 108 130/80 16 - - 10.1 6800 2.3 B+ 3’45 4’50 41 84 1.3 Nl Nl Nl - 1281/06 15/6/06 Nl + Nl 
13. Ramu 891427 120 100/74 18 - - 9.3 6500 1.9 O+ 2’45 5’15 39 79 0.8 Nl Nl Nl - 1312/06 22/6/06 Nl Nl + 
14. Radha 900775 100 110/86 15 - - 6.2 4100 1.7 O- 3’20 6’25 43 95 1.3 Nl + Nl - 1386/06 29/6/06 Nl + Nl 
15. Shankar 901035 104 106/80 16 - + 8.5 4300 1.8 AB+ 2’50 5’30 37 198 1.1 Nl Nl Nl - 1410/06 06/7/06 Nl Nl + 
16. Abirami 902656 88 124/88 16 - - 6.4 4200 1.8 O+ 1’55 7’20 45 132 1.4 Nl Nl Nl - 1431/06 13/7/06 Nl + Nl 
17. Adhirai 904008 84 140/86 14 - - 7.9 5700 2.0 O+ 3’20 6’25 27 126 1.0 Nl Nl Nl - 1450/06 20/7/06 Nl + Nl 
18. Panneerselvam 905804 102 130/88 18 - + 9.6 7800 2.1 B- 3’30 5’45 36 297 0.9 Nl Nl + - 1538/06 03/8/06 Nl Nl + 
19. Arulmary 905351 90 128/84 16 - - 10.8 8900 2.5 B+ 2’45 5’10 34 128 0.8 Nl Nl Nl - 1491/06 03/8/06 Nl Nl Nl 
20. Tamilselvan 902920 94 134/80 15 - - 9.2 7300 2.1 O+ 2’30 5’10 42 89 1.3 Nl Nl Nl - 1403/06 22/8/06 Nl Nl Nl 
21. Sarasu 903313 102 94/60 16 - - 9.5 8100 2.2 A- 3’10 6’05 32 68 1.2 Nl Nl Nl - 1437/06 29/8/06 Nl Nl + 
22. Amutha 932387 94 110/76 14 - - 7.4 5100 1.8 O- 3’30 6’55 44 114 1.3 Nl Nl Nl - 468/07 15/3/07 Nl Nl Nl 
23. Sarasu 932287 86 140/86 14 - - 7.7 4400 1.5 B- 4’00 5’30 38 88 1.1 Nl Nl Nl + 496/07 15/3/07 Nl + Nl 
24. Selvendhran 932531 108 122/86 16 - - 6.9 5300 1.7 A+ 2’55 6’10 23 113 1.0 Nl Nl Nl - 517/07 20/3/07 Nl + Nl 
25. Chandra 935141 112 130/84 14 - - 5.8 4900 1.6 O+ 2’20 5’25 43 93 0.9 Nl +l Nl - 640/07 12/4/07 Nl + Nl 
 
Note: (M) - Male; (F) - Female; (Y) –Yes; (N) – No; (Nl) - Normal; (+) - Findings present; (-) - Negative; (D) – Days; (W) – Weeks; (Mo) – Months; 
 
 
 Appendix B: Master Chart (Continued…) 
 
 
Note: (M) - Male; (F) - Female; (Y) –Yes; (N) – No; (Nl) - Normal; (+) - Findings present; (-) - Negative; (D) – Days; (W) – Weeks; (Mo) – Months; 
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26. Parimala 38 F 936210 23.2 2 1 Y N Ibuprofen 400 12 4D N N N N     N N N N N N N N N N N 1 
27. Karuppasamy 58 M 937309 22.8 3 1 Y N Aspirin 150 45 45D N N N N N Y Y Y N N Y Y N Y N 4 
28. Kamalam 60 F 936006 27.9 2 2 Y N Diclofenac 50 8 3D N N N N N N N N Y N N Y N N Y 1 
29. Sakkarapani 63 M 937262 24.6 4 2 Y N Indomethacin 25 20 12D N Y N N Y Y Y N N N N N N N N 4 
30. Ravi 30 M 922409 23.7 2 1 Y N Nimesulide 100 8 3D Y N N Y N Y N Y N N N N N N N 4 
31. Rathinasamy 65 M 937809 30.2 5 3 Y N Diclofenac 100 6 3D Y N N Y N Y N N N N N Y N N N 4 
32. Elambal 70 F 938443 21.3 1 1 N N Ibuprofen 200 10 4D Y N N Y Y N N N N N N N N N N 6 
33. Elangovan 40 M 938652 24.6 0 - Y N Mefenamic acid 250 12 6D N N N N N N Y N N N N N N N N 2 
34. Swaminathan 65 M 934045 24.2 4 1 Y N Ibuprofen 400 15 5D Y N N N N N N N N N N N N N N 2 
35. Padharnisha 55 F 938301 23.6 5 3 Y N Diclofenac 75 12 6D N N N N N N N N N N N N N N N 1 
36. Selvam 42 M 938828 23.6 2 2 Y N Nimesulide 100 10 5D N N N Y N Y Y N N N N N N N N 4 
37. Sakeel ahmad 24 M 940106 30.8 2 3 Y N Ibuprofen 400 10 4D N Y N N N Y N N N N N N N N N 2 
38. Gomathi 60 F 939020 22.1 1 1 N N Indomethacin 50 4 2D N N N Y N N N N N N N N N N N 1 
39. Arumugam 60 M 940901 22.9 1 1 N N Ibuprofen 400 8 3D Y N N Y N N N N N N N Y N N N 2 
40. Jeyakkodi 61 F 940428 24.2 3 2 Y N Ibuprofen 200 10 4D N N N N N N N N N N N N N N N 1 
41. Vanathiyan 23 M 940919 20.8 0 - Y N Ibuprofen 200 4 2D N N N N N N Y N N N N N N N N 2 
42. Balakrishnan 57 M 941062 23.7 4 2 Y N Mefenamic acid 250 10 5D N N N N N Y N N N N N Y N N N 2 
43. Murugan 60 M 941659 24.4 2 1 Y N Ibuprofen 200 18 1W Y N N Y N Y Y N N N N Y N N N 5 
44. Karuppasamy 55 M 942081 21.8 4 2 Y N Aspirin 150 270 9Mo N N N N N N N Y N N Y Y N Y N 2 
45. Raman 61 M 942219 25.2 1 1 N N Diclofenac 50 5 3D Y Y N Y N Y N N N N N N N N N 4 
46. Pitchaiyan 50 M 942826 22.1 2 1 Y N Ibuprofen 400 25 10D N N N N N Y N N N N N N N N N 1 
47. Raman 61 M 943126 25.8 4 2 Y N Aspirin 150 60 2Mo N N N N N Y N N N N Y Y N Y N 2 
48. Indirani 66 F 941849 23.7 2 1 Y N Indomethacin 25 14 1W N N N N N N N N N N N N N N N 1 
49. Sami ayya 45 M 944443 24.4 0 - Y N Diclofenac 50 10 5D Y N N Y N N N N N N N N N N N 3 
50. Vijayakumar 37 M 944909 27.6 2 2 Y N Ibuprofen 400 12 6D N N N N N Y Y N N N N N N N N 2 
  
Appendix B: Master Chart (Continued…) 
 
18. vital signs       20. Investigations 
 
22. UGI Endoscopy 
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26. Parimala 936210 94 100/70 15 - - 9.6 8600 1.5 O- 3’15 5’30 29 97 1.0 Nl Nl Nl - 661/07 12/4/07 Nl Nl Nl 
27. Karuppasamy 937309 86 170/96 17 + + 8.6 7800 1.6 O+ 3’10 7’40 45 258 1.6 Nl Nl + - 668/07 16/4/07 Nl Nl + 
28. Kamalam 936006 102 102/80 14 - + 7.6 4800 1.4 B+ 3’25 5’05 39 296 1.1 Nl + Nl - 667/07 17/4/07 Nl + Nl 
29. Sakkarapani 937262 114 90/64 18 - - 7.9 6300 1.8 O+ 2’55 5’45 45 106 1.0 Nl Nl Nl - 663/07 17/4/07 Nl + + 
30. Ravi 922409 110 120/80 16 - - 7.2 5200 1.4 A+ 3’10 6’05 52 91 1.3 Nl Nl Nl - 619/07 19/4/07 Nl + Nl 
31. Rathinasamy 937809 120 96/60 18 - + 6.2 4200 1.7 B+ 3’35 6’15 42 152 1.0 Nl Nl Nl - 654/07 19/4/07 Nl Nl + 
32. Elambal 938443 86 110/74 14 - - 8.6 6200 1.4 O+ 2’50 5’20 39 89 1.1 Nl Nl Nl + 707/07 24/4/07 Nl + Nl 
33. Elangovan 938652 96 130/80 14 - - 10.7 7400 2.3 O- 2’35 5’45 32 106 0.9 Nl Nl Nl - 706/07 24/4/07 Nl Nl Nl 
34. Swaminathan 934045 86 136/84 15 - - 9.2 6500 1.7 AB+ 2’10 4’50 38 72 1.0 Nl + + - 732/07 26/4/07 Nl + Nl 
35. Padharnisha 938301 110 94/64 20 - - 6.1 4700 1.6 O+ 3’50 5’50 39 104 1.0 Nl Nl Nl - 736/07 26/4/07 Nl + Nl 
36. Selvam 938828 94 130/84 16 - - 8.3 5100 2.2 O+ 2’40 5’15 45 123 1.0 Nl Nl Nl - 745/07 1/5/07 Nl + Nl 
37. Sakeel ahmad 940106 108 170/96 16 - - 9.2 5200 1.9 B- 3’25 4’45 47 96 1.1 Nl Nl Nl + 783/07 4/5/07 Nl Nl + 
38. Gomathi 939020 90 100/70 15 - - 9.3 6500 1.7 B+ 2’55 5’25 39 79 0.8 Nl Nl Nl - 777/07 4/5/07 Nl Nl Nl 
39. Arumugam 940901 88 110/86 15 - + 9.2 4900 1.6 AB- 3’30 6’25 43 230 1.2 Nl Nl + - 815/07 8/5/07 Nl + Nl 
40. Jeyakkodi 940428 94 106/70 16 - - 8.9 5300 2.1 O- 2’55 5’40 31 98 0.9 Nl Nl Nl - 807/07 8/5/07 Nl Nl Nl 
41. Vanathiyan 940919 90 124/80 16 - - 10.1 5800 1.9 B- 2’20 6’40 35 102 1.0 Nl Nl Nl + 525/07 10/5/07 Nl + Nl 
42. Balakrishnan 941062 104 130/86 14 - + 9.3 5700 1.8 O- 3’25 6’10 37 196 1.0 Nl Nl Nl - 840/07 10/5/07 Nl Nl + 
43. Murugan 941659 96 140/86 18 - + 9.5 8500 2.1 O+ 3’10 5’15 36 207 0.9 Nl Nl Nl - 843/07 17/5/07 Nl + Nl 
44. Karuppasamy 942081 90 138/84 16 - + 8.8 6300 1.8 A+ 2’55 5’20 39 223 1.0 Nl Nl + - 876/07 22/5/07 Nl + Nl 
45. Raman 942219 96 124/86 15 - - 9.3 7400 1.9 O+ 2’35 5’20 42 94 1.2 Nl Nl + - 889/07 22/5/07 Nl Nl Nl 
46. Pitchaiyan 942826 90 104/60 16 - - 9.4 7100 1.8 AB+ 3’20 5’40 39 72 1.0 Nl Nl Nl - 936/07 24/5/07 Nl Nl Nl 
47. Raman 943126 94 150/76 14 - + 8.6 5400 1.6 O- 3’50 6’55 44 214 1.1 Nl Nl + - 939/07 29/5/07 Nl + + 
48. Indirani 941849 76 130/88 14 - - 7.2 4400 1.3 B+ 4’05 5’10 38 89 1.1 Nl Nl Nl - 869/07 31/5/07 Nl + Nl 
49. Sami ayya 944443 98 126/86 16 - - 9.9 6600 1.8 A+ 2’45 6’00 33 118 1.0 Nl Nl Nl + 995/07 7/6/07 Nl Nl + 
50. Vijayakumar 944909 92 120/84 14 - - 8.8 4900 2.4 A+ 2’35 5’25 41 98 0.9 Nl Nl Nl - 983/07 12/6/07 Nl + Nl 
 
Note: (M) - Male; (F) - Female; (Y) –Yes; (N) – No; (Nl) - Normal; (+) - Findings present; (-) - Negative; (D) – Days; (W) – Weeks; (Mo) – Months; 
  
